News

At the Company’s AGM being held today at 11.00 am, the Chairman, Christopher Pearce, will make the following statement.

 “Following the delivery of a profit after tax in 2019, we are pleased to report continued progress throughout the business. We have experienced good growth in services revenues and sales of both TMT^® and TMTpro™ have remained stable over the first 5 months of the year. Despite the challenges of the COVID-19 pandemic, our dedicated staff have ensured we remained fully operational and have delivered 11 projects carried over from 2019 for which we already had samples. A further 10 projects are ongoing and new orders are also being generated. We expect these trends to continue through the rest of the year”

Proteome Sciences Plc (AIM: PRM), the specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, announces that the Company's 2020 Annual General Meeting (the "AGM") will be held at 11.00 am on 26 June 2020 at Nicholson House, Thames Street, Weybridge KT13 8JG. Notification of the AGM and proxy form have been posted to shareholders and will shortly be available on the Company's website. 

Notice of Annual General Meeting 

Letter from the Chairman

Proxy Form

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 30 April 2020.

Proteome Sciences plc (AIM: PRM), notes the recent increase in the Company's share price and confirms that it is not aware of any material basis for this rise.

The Company refers shareholders to its Final Results announcement on 14 April 2020 and its Notice of Results announcement made on 30 March 2020.

Proteome Sciences announces that its Annual Report for the year to 31 December 2019 has been posted to shareholders and is now available on the Company's website. Annual Report and Accounts 2019 

Due to the ongoing social distancing measures, the Board has determined to convene the Annual General Meeting later this quarter as soon as it is possible to provide a safe environment for all wishing to attend.  Formal notice of the Annual General Meeting will therefore be posted to shareholders at a later date.

Loan amendment

On 3 July 2018, the Company entered into a £1 million loan facility with Vulpes Investment Management Private Limited (“VIM”) (the “Loan”), which was incorrectly announced on 3 July 2018 as being a loan facility with Vulpes Life Sciences Fund.  The Vulpes Life Sciences Fund is managed by VIM. 

The Directors of Proteome Sciences are now pleased to announce that the Loan has been amended such that the Loan (of which £700,000 is currently drawn) and all accrued interest is now repayable on 1 May 2021 (previously 31 December 2019).

The Company is pleased to announce its audited results for the year ended 31 December 2019.

Further to our announced intention to publish our audited 2019 full year results on 31 March 2020, the Board wishes to notify shareholders that this will now be postponed until Tuesday April 14^th. This follows advice and additional guidance on financial reporting from the Financial Conduct Authority and the Financial Reporting Council in light of the ongoing coronavirus pandemic. 

he Directors of Proteome Sciences look forward to updating shareholders on the Company’s performance, and on the outlook for 2020, at the time of announcing the 2019 full year results which are scheduled for release on 31 March 2020.

Annual General Meeting

The Annual General Meeting of the Company will take place at the offices of Allenby Capital, 5 St Helen's Place, London EC3A 6AB, at 2.30pm on 29 April 2020.  Formal notice of such will be posted to shareholders with the annual report in April.

The Company received notification yesterday from Vulpes Life Sciences Fund ("Vulpes") that on 28 February 2020 it purchased 256,424 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.00p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,203,158 Ordinary Shares, equivalent to approximately 22 per cent of the issued share capital of the Company.

The Company is pleased to provide a further trading update for the financial year ended 31 December 2019.